AUTHOR=Wei Yong , Zeng Qingye , Cai Lidong , Wang Xingjie , Wang Bin , Shen Chaoying , Li Chao , Wang Caihong , Shen Yahong , Yang Shunhong , Wu Xiaoyu , Liu Yan , Xu Juan , Lu Xiaofeng , Chen Songwen , Zhou Genqing , Liu Shaowen TITLE=Contemporary survival and anticoagulation of patients with atrial fibrillation: A community based cohort study in China JOURNAL=Frontiers in Cardiovascular Medicine VOLUME=9 YEAR=2022 URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.911393 DOI=10.3389/fcvm.2022.911393 ISSN=2297-055X ABSTRACT=Backgrounds

The understanding of death in patients with atrial fibrillation (AF) in China is limited. This study aimed to assess the contemporary survival of AF patients in China and to explore risk factors for deaths.

Methods

This was a prospective community-based cohort study including 559 AF patients, who were followed-up from July 2015 to December 2020.

Results

During 66-month follow-up, there were 200 deaths (56.5% cardiovascular, 40.0% non-cardiovascular, and 3.5% unknown causes) among 559 AF patients with the median age of 76 years. The top three causes of death were heart failure (33.0%), ischemic stroke (17.0%) and cancer (16.5%). Multivariate Cox regression analysis indicated baseline variables positively associated with all-cause death were age (HR: 1.10, 95% CI: 1.08–1.13), AF subtype (HR: 1.37, 95% CI: 1.08–1.73), prior myocardial infarction (HR: 3.40, 95% CI: 1.48–7.78), previous tumor (HR: 2.61, 95% CI: 1.37–4.98), hypoglycemic therapy at baseline (HR: 1.81, 95% CI: 1.13–2.91), but body weight (HR: 0.98, 95% CI: 0.97–1.00) and use of calcium channel blocker (CCB) (HR: 0.62, 95% CI: 0.41–0.95) played a protective role to all-cause death. Of patients who were alive at the end of follow-up, 24.0% were on oral anticoagulants (OAC) alone, 4.5% on dual antithrombotic therapy, 33.1% on antiplatelet agents alone and 38.4% weren't on any antithrombotic medication.

Conclusion

Ischemic stroke still remains one of the leading causes of death and OAC is seriously underused in AF patients in China. Independent risk factors for death are age, AF subtype, previous tumor, prior myocardial infarction, hypoglycemic therapy, low body weight and no CCB use.

Clinical Trial Registration

http://www.chictr.org.cn/ (ChiCTR-ICR-15007036).